- Home
- GLTO vs ALCE Comparison
GLTO vs ALCE Comparison
Compare GLTO & ALCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- ALCE
- Stock Information
- Founded
- GLTO 2011
- ALCE 2019
- Country
- GLTO Denmark
- ALCE United States
- Employees
- GLTO N/A
- ALCE N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- ALCE Power Generation
- Sector
- GLTO Health Care
- ALCE Utilities
- Exchange
- GLTO Nasdaq
- ALCE Nasdaq
- Market Cap
- GLTO 9.5M
- ALCE 8.6M
- IPO Year
- GLTO 2020
- ALCE N/A
- Fundamental
- Price
- GLTO $5.81
- ALCE $1.43
- Analyst Decision
- GLTO Buy
- ALCE
- Analyst Count
- GLTO 1
- ALCE 0
- Target Price
- GLTO $10.00
- ALCE N/A
- AVG Volume (30 Days)
- GLTO 16.5K
- ALCE 753.4K
- Earning Date
- GLTO 11-01-2024
- ALCE 12-03-2024
- Dividend Yield
- GLTO N/A
- ALCE N/A
- EPS Growth
- GLTO N/A
- ALCE N/A
- EPS
- GLTO N/A
- ALCE N/A
- Revenue
- GLTO N/A
- ALCE N/A
- Revenue This Year
- GLTO N/A
- ALCE N/A
- Revenue Next Year
- GLTO N/A
- ALCE N/A
- P/E Ratio
- GLTO N/A
- ALCE N/A
- Revenue Growth
- GLTO N/A
- ALCE N/A
- 52 Week Low
- GLTO $5.62
- ALCE $1.18
- 52 Week High
- GLTO $23.50
- ALCE $266.50
- Technical
- Relative Strength Index (RSI)
- GLTO 25.82
- ALCE 22.75
- Support Level
- GLTO $5.62
- ALCE $1.31
- Resistance Level
- GLTO $6.94
- ALCE $2.20
- Average True Range (ATR)
- GLTO 0.34
- ALCE 0.28
- MACD
- GLTO 0.02
- ALCE -0.01
- Stochastic Oscillator
- GLTO 11.27
- ALCE 15.02
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About ALCE Alternus Clean Energy Inc.
Alternus Clean Energy Inc is an international independent clean energy producer. It develops, installs, owns and operates a diverse portfolio of utility-scale solar photovoltaic power stations (PV parks) in Europe and the USA as a long-term owner. The solar parks benefit from long-term government offtake contracts and/or Power Purchase Agreements (PPAs) with investment grade off-takers, plus energy sales to local power grids. It has approximately 8 operating parks, a total of 44 MWp in operation.